Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + dalteparin + methotrexate + prednisone
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A metronomic chemotherapy regimen consisting of daily dalteparin (a low molecular weight heparin), daily oral cyclophosphamide, twice-weekly oral methotrexate, and daily oral prednisone. This combination is primarily used in the treatment of metastatic breast cancer and employs a metronomic approach, which involves the administration of lower doses of chemotherapeutic agents on a more frequent or continuous schedule to achieve antiangiogenic effects while minimizing toxicity.
02
Targets
DNADHFR (Dihydrofolate reductase)F10 (Factor Xa)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cyclophosphamide + dalteparin + methotrexate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + dalteparin + methotrexate + prednisone.